CERULE, LLC – Trademark Portfolio
Entity Type: 16
CERULE, LLC holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 17 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 4 Nice Classification classes. Currently, 12 trademarks are registered. Notable registered marks include CERULE, CYACTIV, MESENKINE, MIGRATOSE, and PLASMAFLO. The owner is based in KLAMATH FALLS, OR.
P.O. BOX 489
KLAMATH FALLS, OR 97601
Showing of trademarks Trademarks
Trademark Classifications
CERULE, LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Raw and unprocessed agricultural, aquacultural, horticultural and forestry products
Frequently Asked Questions
How many trademarks does CERULE, LLC have?
CERULE, LLC has 19 U.S. trademarks filed with the USPTO. Of these, 12 registered, 4 abandoned, 3 cancelled.
What trademark classes does CERULE, LLC file in?
CERULE, LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 1 (Chemicals), Class 31 (Natural Agricultural Products). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are CERULE, LLC's most well-known trademarks?
CERULE, LLC's registered trademark portfolio includes well-known marks such as CERULE, CYACTIV, MESENKINE, MIGRATOSE, and PLASMAFLO. These are among 12 currently registered trademarks in the portfolio.
What is CERULE, LLC's trademark registration success rate?
CERULE, LLC has a 63% trademark registration rate, with 12 out of 19 resolved applications resulting in successful registration. Currently, 0 applications are pending review.